A randomized controlled trial comparing lithium plus valproic acid versus lithium plus carbamazepine in young patients with type 1 bipolar disorder: the LICAVAL study

Giovani Missio, Doris Hupfeld Moreno, Frederico Navas Demetrio, Marcio Gerhardt Soeiro-de-Souza, Fernando Dos Santos Fernandes, Vivian Boschesi Barros, Ricardo Alberto Moreno, Giovani Missio, Doris Hupfeld Moreno, Frederico Navas Demetrio, Marcio Gerhardt Soeiro-de-Souza, Fernando Dos Santos Fernandes, Vivian Boschesi Barros, Ricardo Alberto Moreno

Abstract

Background: Treatment of bipolar disorder (BD) usually requires drug combinations. Combinations of lithium plus valproic acid (Li/VPA) and lithium plus carbamazepine (Li/CBZ) are used in clinical practice but were not previously compared in a head-to-head trial.

Objective: The objective of this trial was to compare the efficacy and tolerability of Li/VPA versus Li/CBZ in treating type 1 BD in any phase of illness in young individuals.

Methods: LICAVAL was a randomized, unicenter, open-label, parallel-group trial that was conducted from January 2009 to December 2012 in a tertiary hospital in São Paulo, Brazil. Participants were between 18 and 35 years old and were followed up for 2 years. Our primary outcome was the number of participants achieving/maintaining response and remission during the acute and maintenance phases of BD treatment, respectively. Other outcomes assessed were symptom severity and adverse events throughout the study. In the analysis of the primary outcome, we compared groups by using a two-way repeated measures analysis of variance and estimated effect sizes by using Cohen's d.

Results: Of our 64 participants, 36 were allocated to Li/VPA and 28 to Li/CBZ. Our sample was composed predominantly of females (66.6%) and the average age was 27.8 years. A total of 27 (45.0%) participants had depression, 17 (28.3%) had mania/hypomania, and 16 (26.7%) had a mixed state. We found no between-group differences in CGI-BP (Clinical Global Impression Scale modified for use in bipolar disorder) scores (P = 0.326) or in any other outcome. Side effects differed significantly between groups only in the first week of treatment (P = 0.021), and there were more side effects in the Li/VPA group. Also, the Li/VPA group gained weight (+2.1 kg) whereas the Li/CBZ group presented slight weight loss (-0.2 kg).

Conclusion: Our study suggests that Li/VPA and Li/CBZ have similar efficacy and tolerability in BD but that Li/CBZ might have metabolic advantages in the long term.

Trial registration: ClinicalTrials.gov identifier: NCT00976794 . Registered on September 9, 2009.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Consolidated Standards for Reporting of Trials (CONSORT) flow diagram
Fig. 2
Fig. 2
Mean Clinical Global Impression Scale (CGI) scores per group at baseline and after 8 weeks in the LICAVAL study
Fig. 3
Fig. 3
Hamilton Depression Rating Scale and Young Mania Rating Scale - scores per group at baseline and after 8 weeks in the LICAVAL study
Fig. 4
Fig. 4
Cumulative survival per group in the LICAVAL study

References

    1. Berk M. Neuroprogression: Pathways to progressive brain changes in bipolar disorder. Int J Neuropsychopharmacol. 2009;12:441–445. doi: 10.1017/S1461145708009498.
    1. Fornaro M, De Berardis D, Koshy AS, Perna G, Valchera A, Vancampfort D, et al. Prevalence and clinical features associated with bipolar disorder polypharmacy: A systematic review. Neuropsychiatr Dis Treat. 2016;12:719. doi: 10.2147/NDT.S100846.
    1. Grande I, de Arce R, Jiménez-Arriero MA, Lorenzo FGI, Valverde JIF, Balanzá-Martínez V, et al. Patterns of pharmacological maintenance treatment in a community mental health services bipolar disorder cohort study (SIN-DEPRES) Int J Neuropsychopharmacol. 2013;16:513–523. doi: 10.1017/S1461145712000405.
    1. Keck JP, McElroy SL. Carbamazepine and valproate in the maintenance treatment of bipolar disorder. J Clin Psychiatry. 2002;63:13–17.
    1. Granneman GR, Schneck DW, Cavanaugh JH, Witt GF. Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium. J Clin Psychiatry. 1996;57:204–206.
    1. Geddes JR, Rendell JM, Goodwin GM, investigators B, others BALANCE: a large simple trial of maintenance treatment for bipolar disorder. World Psychiatry. 2002;1:48.
    1. Sharma V, Persad E, Mazmanian D, Karunaratne K. Treatment of rapid cycling bipolar disorder with combination therapy of valproate and lithium. Can J Psychiatr. 1993;38:137–139. doi: 10.1177/070674379303800213.
    1. Calabrese JR, Delucchi GA. Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry. 1990;147:431. doi: 10.1176/ajp.147.4.431.
    1. Reischies FM, Hartikainen J, Berghöfer A. Initial lithium and valproate combination therapy in acute mania. Neuropsychobiology. 2002;46:22–27. doi: 10.1159/000068020.
    1. Denicoff KD, Smith-Jackson EE, Disney ER, Ali SO, Leverich GS, Post RM. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry. 1997;58:470–478. doi: 10.4088/JCP.v58n1102.
    1. Bocchetta A, Chillotti C, Severino G, Ardau R, Del Zompo M. Carbamazepine augmentation in lithium-refractory bipolar patients: A prospective study on long-term prophylactic effectiveness. J Clin Psychopharmacol. 1997;17:92–96. doi: 10.1097/00004714-199704000-00005.
    1. Shukla S, Cook BL, Miller M. Lithium-carbamazepine versus lithium-neuroleptic prophylaxis in bipolar illness. J Affect Disord. 1985;9:219–222. doi: 10.1016/0165-0327(85)90051-5.
    1. Baethge C, Baldessarini RJ, Mathiske-Schmidt K, Hennen J, Berghöfer A, Müller-Oerlinghausen B, et al. Long-term combination therapy versus monotherapy with lithium and carbamazepine in 46 bipolar I patients. J Clin Psychiatry. 2005;66:174–182. doi: 10.4088/JCP.v66n0204.
    1. Kramlinger K, Post RM. Adding lithium carbonate to carbamazepine: Antimanic efficacy in treatment-resistant mania. Acta Psychiatr Scand. 1989;79:378–385. doi: 10.1111/j.1600-0447.1989.tb10273.x.
    1. Costanzo ED, Schifano F. Lithium alone or in combination with carbamazepine for the treatment of rapid-cycling bipolar affective disorder. Acta Psychiatr Scand. 1991;83:456–459. doi: 10.1111/j.1600-0447.1991.tb05575.x.
    1. Freeman MP, Stoll AL. Mood stabilizer combinations: A review of safety and efficacy. Am J Psychiatry. 1998;155:12–21. doi: 10.1176/ajp.155.1.12.
    1. Müller-Oerlinghausen B. Drug interactions with lithium. CNS Drugs. 1999;11:41–48. doi: 10.2165/00023210-199911010-00004.
    1. Arana GW. An overview of side effects caused by typical antipsychotics. J Clin Psychiatry. 2000;61:5–11.
    1. Kishimoto A. The treatment of affective disorder with carbamazepine: Prophylactic synergism of lithium and carbamazepine combination. Prog Neuro-Psychopharmacol Biol Psychiatry. 1992;16:483–493. doi: 10.1016/0278-5846(92)90054-I.
    1. Goodwin FK. Rationale for using lithium in combination with other mood stabilizers in the management of bipolar disorder. J Clin Psychiatry. 2003;64:18–24. doi: 10.4088/JCP.v64n0104.
    1. Ministério da Saúde brasileiro. Relação Nacional de Medicamentos Essenciais 2017. (accessed July 1, 2018).
    1. Governo do Estado de São Paulo. Relação estadual de medicamentos do componente especializado da assistencia farmacêutica 2018. (accessed July 1, 2018).
    1. Moher D, Schulz KF, Altman DG. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;357:1191–1194. doi: 10.1016/S0140-6736(00)04337-3.
    1. General Assembly of the World Medical Association World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Coll Dent. 2014;81:14–18.
    1. First MB, Spitzer RL, Gibbon M, Williams JB, Del Ben CM, Zuardi AW, et al. Structured Clinical Interview for DSM-IV® Axis I Disorders (SCID-I), Clinician Version, Administration Booklet. New York: American Psychiatric Association; 2013.
    1. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): The CGI-BP. Psychiatry Res. 1997;73:159–171. doi: 10.1016/S0165-1781(97)00123-6.
    1. Hamilton M. A rating scale for depression. J Neurol J Neurol Neurosurg Psychiatry. 1960;23:56. doi: 10.1136/jnnp.23.1.56.
    1. Ramos de Carvalho TF, Garcia Lima M, Soares Azevedo RC, Caetano D. Tradução do inglês para o português do questionário de auto-avaliação da Escala de Hamilton para a Depressão. J Bras Psiquiatr. 1993;42:255–260.
    1. Young R, Biggs J, Ziegler V, Meyer D. A rating scale for mania: Reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–435. doi: 10.1192/bjp.133.5.429.
    1. Vilela J, Crippa J, Del-Ben C, Loureiro S. Reliability and validity of a Portuguese version of the Young Mania Rating Scale. Braz J Med Biol Res. 2005;38:1429–1439. doi: 10.1590/S0100-879X2005000900019.
    1. Keck PE, McElroy SL. Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. J Clin Psychiatry. 2003;64:1426–1435. doi: 10.4088/JCP.v64n1205.
    1. Johnson FR, Özdemir S, Manjunath R, Hauber AB, Burch SP, Thompson TR. Factors that affect adherence to bipolar disorder treatments: A stated-preference approach. Med Care. 2007;45:545–552. doi: 10.1097/MLR.0b013e318040ad90.
    1. Domecq JP, Prutsky G, Leppin A, Sonbol MB, Altayar O, Undavalli C, et al. Drugs commonly associated with weight change: A systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100:363–370. doi: 10.1210/jc.2014-3421.
    1. Andrews Gavin. Efficacy, Effectiveness and Efficiency in Mental Health Service Delivery. Australian & New Zealand Journal of Psychiatry. 1999;33(3):316–322. doi: 10.1046/j.1440-1614.1999.00581.x.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться